

The promises of Treg and Interleukin-2 therapies for autoimmune and inflammatory diseases, allergy, transplantation & cancer



**Centre International de Conférences Sorbonne Université
October 21-24, 2026**

International Organizing Committee

**Abul Abbas, Christophe Benoist, Jeff Bluestone, Laurie Dempsey, David Klatzmann (Chair),
Thomas Malek, Qizhi Tang, Shimon Sakaguchi, Georges Tsokos, Lucy Walker**

Local Organizing Committee

Caroline Aheng, Encarnita Mariotti-Ferrandiz, Michelle Rosenzweig, Nicolas Tchitchek

Current list of confirmed invited speakers

**Abul Abbas; Christophe Benoist, Christoph Binder; Marina Cavazzana; Jens Humrich; Ron
Germain; Wolfgang Kastenmueller; David Klatzmann; Vijay Kuchroo; Nigel Leigh; Zhanguo Li;
Wan-Lin Lo; Ziad Mallat; Tom Malek; Adel Nada; Sacha Rudensky; Naomi Taylor; George Tsokos;
Serena Zacchigna; Jonathan Zalevsky; David Zemmour**

Sponsors



Partners



18.00 - Opening Session

Welcome words: **Abul Abbas**

Keynote lectures

Chair: Abul Abbas

- **Treg 2026 – Alexander Rudensky, Ludwig Center MSK, New York**
- **IL-2 based therapies 2026 – David Klatzmann, Sorbonne University, Paris**

20.00 - Welcome reception

Thursday 22

9.00 Session I - *On mechanistic: Treg development and heterogeneity*

Chair: Lucy Walker

1. David Zemmour: Treg cosmology in the immgenT datasets
2. Wan-Lin Lo: in search of the lost Zap70 signal

Talks from abstracts

- a. BLIMP1 as a transcriptional rheostat for IL-2 responsiveness in Tregs, autoimmunity and T-cell malignancy - Suyasha Roy
- b. Trophic functions of uterine-resident Tregs - Encarnita Mariotti-Ferrandiz

10.30 – 11.00 – Coffee break

11.00 Session II – *Lessons and successes from clinical trials with native IL-2*

Chair: George Tsokos

3. Zhanguo Li: Ld-IL2 treatment of autoimmune diseases in China: from trials to clinical application
4. Jonathan Zalevsky: Update on the Clinical Development of Repegaldesleukin- Results from Phase 2 Trials in Atopic Dermatitis and Alopecia Areata
5. Ziad Mallat: Targeting Tregs with IL-2 in patients with atherosclerotic cardiovascular disease

Talks from abstracts

- a. Low-dose interleukin-2 for recurrent early pregnancy loss - Michelle Rosenzweig
- b. IL-2 in type one diabetes: lessons from the DIABIL-2 and DIAREP trials - Chloe Amouyal

13.00 – 14.00 – Lunch

14.00 Session III - *On mechanistic: activation and metabolism*

Chair: Vijay Kuchroo

6. Wolfgang Kastenmueller: The spatial biology of IL-2 reveals a new framework for CD8 T Cell fate decisions
7. Tom Malek: Co-targeting the CD40L pathway potentiates Treg-selective IL-2-driven therapy
8. George Tsokos: Treg cell metabolism in SLE

Talks from abstracts

- c. Stability and function of Foxp3 Tregs at steady state and in inflammatory conditions. Benoit Salomon
- d. Altered activation of Tregs by muteins - Nicolas Tchitchek

16.00 – 16.30– Coffee break

16.30 Session IV – *CNS and the control of inflammation*

Chair: Patrice Cacoub

9. Vijay Kuchroo: Regulation of Neuroimmune Interactions and Neuroinflammation
10. Nigel Leigh: IL-2 in Amyotrophic Lateral Sclerosis IL-2
11. Pierre Ellul: IL-2 in autism spectrum disorders
12. Marion Leboyer: IL-2 in depression

18.30 End of the day

20.00 speakers' dinner

Friday 23

9.00 Session V - *IL-2 in cardiovascular diseases (session sponsored by the TiILT EU research grant)*

Chair: Ziad Mallat

13. Christoph Binder: on Treg, OSE and inflammatory CVD
14. Thomas Vazquez: OSE-targeted IL-2
15. Serena Zacchigna: IL-2 and cardiac infarction recovery
16. Jens Humrich: IL-2 and cardiovascular SLE

10.30 – 11.00 - Coffee break

11.00 - Session VI - *Treg cell therapies*

Chair: Olivier Boyer

1. Naomi Taylor: Engineering TCR fuzzy logic in CAR T cells: implications for Tregs
2. Marina Cavazzana: FoxP3-transduced CD4 T cells for IPEX
3. Marc Martinez-Llordella: Clinical use of engineered Tregs for the induction of tolerance in Autoimmunity and Transplantation

Talks from abstracts

- e. Autoregulated inflammation-activated IL-2 self-sufficient Tregs: Janie Robert
- f. Engineering Regulatory T Cells with Chimeric Allergen Receptors for the Treatment of Allergies: Yannick Muller
- g. Generation of functionally stable iTreg cells for controlling GvHD - Ryoji Kawakami
- h. *Ex vivo* Expandable Human $\alpha\beta$ Double-Negative T Cells Exhibit Regulatory Features and Suppressive Activity: Goeun Jun

13.30 - 14.30 - Lunch

14.30- Session VII – *on Treg antigen specificities*

Chair: Encarnita Mariotti-Ferrandiz

4. Ron Germain: Probing Immunity at the Single Cell Level in Tissues Using Highly Multiplex 2D and 3D Imaging
5. Christophe Benoist: Regulating the regulators

Talks from abstracts

- i. Ecology of Treg TCR specificities in humans - Helene Vantomme
- j. Not all Treg TCRs are equal - Maria De Temple Llaverro
- k. *in silico* identification of TCR specificities - Céline Albalaa
- l. Epithelial MHC II antigen presentation dynamically informs intestinal homeostasis and injury: Vladyslav Holiar

16.30 - 17.00 – Coffee break

17.00- Session VIII - *Engineering IL-2*

Chair: David Klatzmann

Talks from abstracts

- m. Immune activation and clinical responses with STK-012, an α/β IL-2 Receptor Biased Partial Agonist plus Pembrolizumab / Chemotherapy in PD-L1 Negative Non-Squamous NSCLC - Martin Oft
- n. EGL-003, a Treg-biased IL-2 mutein preserving full agonist activity, mobilizes tissue Treg function preclinically and preferentially activates effector/memory skin-homing Tregs in humans - Jonathan Back

- o.* Interleukin-2 engineering: walking a tightrope between functional optimization and biophysical liabilities - Rojas Gertrudis
- p.* Engineering trispecific IL-2 receptor agonistic antibodies through geometry optimization for enhanced Treg targeting: Vanshika Malviya
- q.* Topical IL-2 Delivery to the Hair Follicle via Cutibacterium acnes: A Microbiome-Enabled Treg Activation Strategy for Alopecia Areata: Decrulle Antoine

18.15 End of the day

Saturday 24

9.00 Session IX- *IL-2/Treg and the pathophysiology of autoimmune diseases*

Chair: Jens Humrich

- r.* Interferon-stimulated gene signature predicts clinical response to low-dose IL-2 in autoimmune diseases - Nicolas Tchitchek
- s.* A Treg TCR signature of low-dose IL-2 treatment in humans - Martin Pezous
- t.* Induced regulatory T cells from patients with primary biliary cholangitis are suppressive and stable and are different from natural regulatory T cells - Irune Lasa Elozegi
- u.* Tregs in rheumatology - Marie Binignat
- v.* Dysregulation of the Treg-IL-2 axis in inflammatory myopathies: from pathophysiology to targeted intervention- Jens Humrich
- w.* Computational solution for the analysis of flow cytometry samples in SMART - a multi-center longitudinal clinical study in type 1 diabetes. Astrid Fabri

10.30 – 11.00 – Coffee break

11.00 Session X – *IL-2 and Tregs: the pharma perspective*

Chair: Abul Abbas

- 6. Christie Fanton /Nektar: Early molecular responses to rezpegaldesleukin across multiple immune pathways dysregulated in atopic dermatitis
 - 7. William Hariri/ILTOO: IL-2 in neuroinflammatory diseases
 - 8. Adel Nada/Trutina: The future of Treg cell therapies
- Round Table: What 's next?

13.00 End of the meeting